X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-specialty-drug-tildrakizumab-makes-it-to-chinas-reimbursement-list/articleshow/105967100.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.expresspharma.in/sun-pharma-gets-china-nmpa-approval-for-ilumetri-to-treat-moderate-to-severe-plaque-psoriasis/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067
https://www.prnewswire.com/news-releases/sun-pharma-to-present-clinical-data-abstracts-for-ilumya-tildrakizumab-asmn-in-patients-with-moderate-to-severe-plaque-psoriasis-at-2022-aad-annual-meeting-301510000.html
https://www.biospace.com/article/releases/sun-pharma-s-pr-ilumya-and-8482-tildrakizumab-injection-now-available-to-help-canadians-living-with-moderate-to-severe-plaque-psoriasis/?s=71
https://www.fiercepharma.com/marketing/coffee-talk-sun-brings-ilumya-patient-stories-to-light-informal-diner-meetups
https://www.prnewswire.com/news-releases/sun-pharma-announces-5-year-sustained-efficacy-and-safety-results-for-ilumya-tildrakizumab-asmn-in-patients-with-moderate-to-severe-plaque-psoriasis-301164297.html
https://www.clinicaltrialsarena.com/news/sun-pharma-ilumya-psoriasis/
https://www.prnewswire.com/news-releases/sun-pharma-announces-5-year-sustained-efficacy-and-safety-results-for-ilumya-tildrakizumab-asmn-in-patients-with-moderate-to-severe-plaque-psoriasis-301164297.html
https://www.prnewswire.com/news-releases/almirall-sa-alm-announces-approval-of-the-reimbursed-price-for-ilumetri-tildrakizumab-in-france-for-the-treatment-of-adult-patients-with-severe-chronic-plaque-psoriasis-301150586.html
https://www.globenewswire.com/news-release/2020/10/13/2107628/0/en/AnaptysBio-Reports-Positive-Topline-Data-from-GALLOP-Phase-2-Clinical-Trial-of-Imsidolimab-in-Moderate-to-Severe-Generalized-Pustular-Psoriasis-GPP.html
https://www.pharmacompass.com/pdf/news/sun-pharma-announces-the-launch-of-ilumya-tildrakizumab-for-treatment-of-plaque-psoriasis-in-japan-1601966777.pdf
https://www.moneycontrol.com/news/business/sun-pharma-gets-nod-from-japan-govt-for-plaque-psoriasis-treatment-drug-5475591.html
https://www.hikma.com/media/2808/sun-agreement-ilumya-final-hikma-version.pdf
https://www.prnewswire.com/news-releases/sun-pharma-announces-long-term-insights-into-the-clinical-use-of-ilumya-tildrakizumab-asmn-in-a-cross-section-of-people-living-with-moderate-to-severe-plaque-psoriasis-301075266.html
https://www.prnewswire.com/news-releases/sun-pharma-plans-to-present-clinical-insights-from-25-data-abstracts-across-its-dermatology-portfolio-at-the-2020-aad-virtual-meeting-experience-301074129.html
http://www.pharmatimes.com/news/smc_rejects_orkambi,_accepts_four_medicines_1297290
https://www.biospectrumasia.com/news/34/14125/sun-pharma-announces-regulatory-filing-of-tildrakizumab-in-japan-.html
http://www.pharmatimes.com/news/rcgp_warns_new_pm_that_we_cannot_risk_no-deal_disruption_1295843
https://www.fiercepharma.com/pharma-asia/top-indian-drugmakers-expand-china-as-country-pressures-generic-costs
https://www.prnewswire.com/news-releases/sun-pharma-announces-late-breaking-phase-2-data-showing-potential-of-ilumya-tildrakizumab-asmn-to-improve-joint-and-skin-symptoms-of-psoriatic-arthritis-300867695.html
https://endpts.com/chi-med-cuts-surufatinib-phiii-short-fda-greenlights-herceptin-copycat-from-amgen-allergan/
https://www.prnewswire.com/news-releases/sun-pharma-announces-the-availability-of-ilumya-tildrakizumab-asmn-in-the-united-states-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-300736007.html
https://www.ema.europa.eu/documents/product-information/ilumetri-epar-product-information_en.pdf
https://economictimes.indiatimes.com/markets/stocks/news/sun-pharma-jumps-2-as-partner-gets-drug-nod/articleshow/65866649.cms
https://www.indiainfoline.com/article/news-top-story/sun-pharma-gains-2-after-receiving-approval-from-european-commission-118091900337_1.html
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/07/news_detail_002994.jsp&mid=WC0b01ac058004d5c1
Market Place
Share 
